financetom
Business
financetom
/
Business
/
Pulsar Helium Signs Deal to Acquire 80% of Quantum Hydrogen from Oscillate in All-Share Transaction
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pulsar Helium Signs Deal to Acquire 80% of Quantum Hydrogen from Oscillate in All-Share Transaction
Nov 4, 2025 5:04 AM

07:39 AM EST, 11/04/2025 (MT Newswires) -- Pulsar Helium ( PSRHF ) earlier Tuesday said it signed a definitive agreement with Oscillate to supersede the non-binding term sheet announced on Sept. 2, 2025, to acquire up to 100% of Oscillate's wholly owned subsidiary, Quantum Hydrogen in an all-share transaction.

A statement noted that, under the agreement, Pulsar is to acquire 80% of the issued share capital of Quantum from Oscillate in consideration of the issuance of new Pulsar common shares having an aggregate value of US$400,000, and to be issued in five equal monthly tranches of US$80,000 each over a five-month period commencing upon receipt of TSX Venture Exchange approval to the transaction.

The company said that the number of consideration shares in each tranche will be determined by the 30-day volume-weighted average price (VWAP) of Pulsar's shares on the TSXV prior to each issuance, subject to the minimum price allowable by the TSXV.

The company was also granted the option to acquire the remaining 20% of the Quantum shares from Oscillate within 18 months for an additional US$400,000 in Pulsar shares, issuable under the same terms and pricing mechanism.

A statement further noted that Quantum holds exclusive mineral rights for non-hydrocarbon gases in Minnesota (59,100 gross acres) that are located in the St. Louis and Itasca Counties, to the west of Pulsar's flagship Topaz project.

"The company also notes that Neil Herbert, a director of Pulsar, is a minority shareholder in Oscillate, and accordingly has abstained from participating in Pulsar's board's deliberations and voting on the transactions, in line with corporate governance best practices," said the company.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Warship builder TKMS makes stock market debut in latest sign of defence asset boom
Warship builder TKMS makes stock market debut in latest sign of defence asset boom
Oct 19, 2025
FRANKFURT, Oct 20 (Reuters) - Warship builder TKMS will make its stock market debut in Frankfurt on Monday, the latest move by parent Thyssenkrupp to simplify its structure and take advantage of growing demand globally for defence assets. Shares in the company will start trading around 0700 GMT on Frankfurt's stock exchange in a spin-off from Thyssenkruppthat will see the...
Germany plans to order 15 more US-made F-35 jets, Der Spiegel reports
Germany plans to order 15 more US-made F-35 jets, Der Spiegel reports
Oct 19, 2025
BERLIN, Oct 20 (Reuters) - German Defence Minister Boris Pistorius intends to order an additional 15 F-35 fighter jets from U.S. manufacturer Lockheed Martin ( LMT ), according to confidential documents prepared for the parliament's budget committee, Der Spiegel reported on Monday. The supplementary procurement is listed among military projects, with planners estimating a budget requirement of 2.5 billion euros...
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
Oct 19, 2025
LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances Accord B.V.'s commitment to improving global access to plasma-derived medicines and strengthens its ability to meet the increasing demand for life-saving plasma therapies worldwide. Prothya Biosolutions...
iPhone 17 outsells predecessor by 14% in early China, US sales, research firm says
iPhone 17 outsells predecessor by 14% in early China, US sales, research firm says
Oct 19, 2025
BEIJING (Reuters) -Apple's ( AAPL ) iPhone 17 series outperformed its predecessor in early sales in China and the United States, research firm Counterpoint said on Monday. The newer models outsold the iPhone 16 series by 14% during their first 10 days of availability in the two countries, Counterpoint said in a report. Sales of the base model iPhone 17...
Copyright 2023-2026 - www.financetom.com All Rights Reserved